Trials / Completed
CompletedNCT00715247
Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 726 (actual)
- Sponsor
- University of Utah · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
The purpose of this project is to find genes whose mutations cause Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis.
Detailed description
Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF), also known as the Philadelphia Chromosome negative myeloproliferative disorders (MPDs), are not congenital, but acquired. The purpose of this project is to find genes whose mutations cause these disorders, as well as improve diagnostic measures for these diseases. When this is accomplished new therapies to control and eventually cure the disease can be designed. All subjects will be asked to donate 4-6 teaspoons of blood. On occasion, if the blood cells from a particular sample do not grow well and the DNA from that sample is used up or other tests are needed, we may ask to collect additional samples. In patients who have undergone a bone marrow biopsy as part of their clinical evaluation, we will test the reproducibility between pathologists for the revised 2008 WHO diagnostic criteria to diagnose myeloproliferative disorders (MPD).
Conditions
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2008-07-15
- Last updated
- 2019-10-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00715247. Inclusion in this directory is not an endorsement.